While JNK3 holds promise as a therapeutic target for neurodegenerative disorders such as Huntington’s, Parkinson’s, and Alzheimer’s diseases, there remains a gap in the market for effective JNK3 inhibitors. The gene discussed is MAPK10; the disease is early-onset autosomal dominant Alzheimer disease.